A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer
Conditions: Metastatic Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Pyrotinib; Drug: SHR6390; Drug: Letrozole; Drug: Capecitabine Sponsors: Jinming Yu; Jiangsu HengRui Medicine Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials